RareResearch.AI
← Back to atlas

E394K

Category 3/4 — Most DruggableUncertain significanceTransmembrane · predictedSource card
Glutamic acidLysine at position 394 · Cytoplasmic loop 2 · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference
Wild-type E394 — ionic bond to R375
Fullscreen ↗
DynaMut2 mutant · E394K
Mutant K394 — ionic bond to R522 lost (10 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

10 lost1 gained8 preserved
Interaction typeWild-type partnerMutant partnerStatus
Ionic bondR375Lost
Ionic bondR522Lost
Hydrogen bondR375Lost
Hydrogen bondV390V390Preserved
Hydrogen bondE391Lost
Hydrogen bondF397F397Preserved
Hydrogen bondG398G398Preserved
Hydrogen bondR522Lost
Polar contactR375Lost
Polar contactV390V390Preserved
Polar contactE391E391Preserved
Polar contactF397Lost
Polar contactG398G398Preserved
Polar contactR522Lost
Van der WaalsW371Lost
Van der WaalsR522Gained
HydrophobicW371W371Preserved
HydrophobicF374F374Preserved
HydrophobicV390Lost

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.07kcal/mol
Destabilising — mild
AlphaMissense
0.742
likely pathogenic
AlphaFold pLDDT
82
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationUncertain significance
Review statuscriteria provided, multiple submitters, no conflicts
Associated conditionsAutosomal dominant nonsyndromic hearing loss 6; WFS1-Related Spectrum Disorders; Cataract 41; Wolfram syndrome 1; Type 2 diabetes mellitus; Wolfram-like syndrome
Population frequency (gnomAD v4)Ultra-rare · AF 0.0020%
cDNA changec.1180G>A
ClinVar accessionVCV000904869
Last evaluated2024/03/11 00:00

Observed at very low frequency in gnomAD.

Full Variant Card

WFS1 Wolframin — E394K Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Glutamic acid → Lysine at position 394. Cytoplasmic loop 2. ClinVar Uncertain significance, AlphaMissense 0.742, DynaMut2 ΔΔG -0.07 kcal/mol (destabilising).


Identity

FieldValue
VariantE394K (p.Glutamic acid394Lysine)
DNA changec.1180G>A
Gene · ProteinWFS1 · Wolframin (890 aa)
UniProtO76024 · WFS1_HUMAN
ClinVar accessionVCV000904869
Amino acid changeGlutamic acid (E) → Lysine (K)

Structural Context

FieldValue
AlphaFold modelAF-O76024-F1, v6
pLDDT at residue 39482.06 — well-folded
DomainCytoplasmic loop 2
Position contextLoop region · position 394 sits between transmembrane segments, solvent-accessible
IDR flagNo — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 394 sits in a connecting loop between transmembrane helices. Loop residues are typically solvent-exposed and often contribute to interhelical contacts or serve as recognition sites for binding partners. The wild-type residue is negatively charged (glutamate — carboxylate); the mutant is positively charged (lysine — primary amine). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.


Computational Predictions

AlphaMissense

FieldValue
am_pathogenicity0.7422
am_classlikely pathogenic
InterpretationLikely pathogenic (threshold 0.564)

DynaMut2

FieldValue
ΔΔG (kcal/mol)-0.07 (Destabilising)
Job ID178092121707
Result URLhttps://biosig.lab.uq.edu.au/dynamut2/results_prediction/178092121707

Clinical Evidence

FieldValue
ClassificationUncertain significance
Review statuscriteria provided, multiple submitters, no conflicts
Last evaluated2024/03/11 00:00
InheritanceAutosomal dominant pattern indicated by associated DFNA6/14/38 (WFS1 hearing loss 6).
WFS1 variant landscapeE394K is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)
  • Autosomal dominant nonsyndromic hearing loss 6
  • WFS1-Related Spectrum Disorders
  • Cataract 41
  • Wolfram syndrome 1
  • Type 2 diabetes mellitus
  • Wolfram-like syndrome

Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=0.07 < 2 kcal/mol (fold intact) + AlphaMissense 0.742 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=0.07 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.742. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.


Files in this folder

  • AF-O76024-F1-model_v6.pdb — AlphaFold structure
  • E394K_molstar_viewer.html — interactive 3D viewer (auto-highlights position 394 with ball-and-stick + neighbors within 5Å)
  • E394K_variant_card.md — this card (source of truth)
  • E394K_variant_card.html — styled printable card
  • E394K_dynamut2_summary.html — clean offline DynaMut2 result card
  • dynamut2_result.json — structured result data
  • dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
  • E394K_wildtype_interactions.pse / E394K_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the E394K PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download E394K PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.